BioCentury | Nov 19, 2015
Product R&D

Bugs against chlamydia

...have it," he added. At least two other companies have chlamydia vaccines in preclinical development. BigDNA...
...already has an undisclosed pharma partner for a C. difficile vaccine. Companies and Institutions Mentioned BigDNA...
BioCentury | Dec 20, 2010
Emerging Company Profile

BigDNA: Fewer Shots on Goal

...for the disease, require multiple booster injections or an adjuvant to trigger an immune response. BigDNA...
...number of immunizations. But DNA vaccines in general have achieved limited success in the clinic. BigDNA...
...BigDNA can produce vaccine within weeks vs. months for egg and cell-based technologies. March estimates BigDNA...
Items per page:
1 - 2 of 2
BioCentury | Nov 19, 2015
Product R&D

Bugs against chlamydia

...have it," he added. At least two other companies have chlamydia vaccines in preclinical development. BigDNA...
...already has an undisclosed pharma partner for a C. difficile vaccine. Companies and Institutions Mentioned BigDNA...
BioCentury | Dec 20, 2010
Emerging Company Profile

BigDNA: Fewer Shots on Goal

...for the disease, require multiple booster injections or an adjuvant to trigger an immune response. BigDNA...
...number of immunizations. But DNA vaccines in general have achieved limited success in the clinic. BigDNA...
...BigDNA can produce vaccine within weeks vs. months for egg and cell-based technologies. March estimates BigDNA...
Items per page:
1 - 2 of 2